{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:41:05Z","timestamp":1792190465592,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03578-4","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:40:01Z","timestamp":1779529201000},"page":"3871-3885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Zhenggang","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingbo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanzhi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfeng","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqiang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichuan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houjie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieer","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyi","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukui","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"4","key":"3578_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.gastha.2022.04.007","volume":"1","author":"K Baria","year":"2022","unstructured":"Baria K, De Toni EN, Yu B, Jiang Z, Kabadi SM, Malvezzi M. Worldwide incidence and mortality of biliary tract cancer. Gastro Hep Adv. 2022;1(4):618\u201326.","journal-title":"Gastro Hep Adv."},{"issue":"14","key":"3578_CR2","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1097\/CM9.0000000000002258","volume":"135","author":"S Chen","year":"2022","unstructured":"Chen S, Han K, Song Y, Liu S, Li X, Wang S, et al. Current status, trends, and predictions in the burden of gallbladder and biliary tract cancer in China from 1990 to 2019. Chin Med J (Engl). 2022;135(14):1697\u2013706.","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"3578_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.21147\/j.issn.1000-9604.2024.05.02","volume":"36","author":"J Zhou","year":"2024","unstructured":"Zhou J, Tan G, Zhang L, Xie G, Chen W, Zhang X, et al. Epidemiology of biliary tract cancer in China: a narrative review. Chin J Cancer Res. 2024;36(5):474\u201388.","journal-title":"Chin J Cancer Res"},{"issue":"12","key":"3578_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/jhbp.1001","volume":"28","author":"S Osataphan","year":"2021","unstructured":"Osataphan S, Mahankasuwan T, Saengboonmee C. Obesity and cholangiocarcinoma: a review of epidemiological and molecular associations. J Hepatobiliary Pancreat Sci. 2021;28(12):1047\u201359.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"6","key":"3578_CR5","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.jhep.2022.07.022","volume":"77","author":"M Vithayathil","year":"2022","unstructured":"Vithayathil M, Khan SA. Current epidemiology of cholangiocarcinoma in Western countries. J Hepatol. 2022;77(6):1690\u20138.","journal-title":"J Hepatol"},{"issue":"13","key":"3578_CR6","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.3390\/cancers15133312","volume":"15","author":"JH Lo","year":"2023","unstructured":"Lo JH, Agarwal R, Goff LW, Heumann TR. Immunotherapy in biliary tract cancers: current standard-of-care and emerging strategies. Cancers (Basel). 2023;15(13):3312.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"3578_CR7","doi-asserted-by":"publisher","first-page":"959","DOI":"10.4251\/wjgo.v15.i6.959","volume":"15","author":"W Leowattana","year":"2023","unstructured":"Leowattana W, Leowattana T, Leowattana P. Paradigm shift of chemotherapy and systemic treatment for biliary tract cancer. World J Gastrointest Oncol. 2023;15(6):959\u201372.","journal-title":"World J Gastrointest Oncol"},{"key":"3578_CR8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"3578_CR9","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.32604\/or.2025.069027","volume":"33","author":"S Kidoikhammouan","year":"2025","unstructured":"Kidoikhammouan S, Saengboonmee C, Wongkham S, Seubwai W. Molecular mechanisms of Gemcitabine resistance in cholangiocarcinoma. Oncol Res. 2025;33(12):3679\u201399.","journal-title":"Oncol Res"},{"issue":"2","key":"3578_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.21037\/cco-22-93","volume":"12","author":"M LaPelusa","year":"2023","unstructured":"LaPelusa M, Heumann T, Goff L, Agarwal R. Targeted therapies in advanced biliary tract cancers-a narrative review. Chin Clin Oncol. 2023;12(2):14.","journal-title":"Chin Clin Oncol"},{"issue":"8","key":"3578_CR11","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s11864-024-01243-y","volume":"25","author":"S Yue","year":"2024","unstructured":"Yue S, Zhang Y, Zhang W. Recent advances in immunotherapy for advanced biliary tract cancer. Curr Treat Opt Oncol. 2024;25(8):1089\u2013111.","journal-title":"Curr Treat Opt Oncol"},{"key":"3578_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241235799","volume":"16","author":"HC Wilbur","year":"2024","unstructured":"Wilbur HC, Azad NS. Immunotherapy for the treatment of biliary tract cancer: an evolving landscape. Ther Adv Med Oncol. 2024;16:17588359241235799.","journal-title":"Ther Adv Med Oncol"},{"key":"3578_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.768009","volume":"11","author":"A Manne","year":"2021","unstructured":"Manne A, Woods E, Tsung A, Mittra A. Biliary tract cancers: treatment updates and future directions in the era of precision medicine and immuno-oncology. Front Oncol. 2021;11:768009.","journal-title":"Front Oncol"},{"issue":"11","key":"3578_CR14","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.3390\/cancers12113182","volume":"12","author":"S De Lorenzo","year":"2020","unstructured":"De Lorenzo S, Tovoli F, Mazzotta A, Vasuri F, Edeline J, Malvi D, et al. Non-alcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its prognostic role. Cancers (Basel). 2020;12(11):3182.","journal-title":"Cancers (Basel)"},{"key":"3578_CR15","unstructured":"AstraZeneca Inc. Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer. Wilmington, DE: AstraZeneca Inc.; 2023."},{"key":"3578_CR16","unstructured":"Center for Drug Evaluation N. Listed drug information details. Beijing, China: Center for Drug Evaluation, NMPA; 2024."},{"key":"3578_CR17","doi-asserted-by":"crossref","unstructured":"Oh D-Y, A. RH, Qin S, Chen L-T, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence. 2022;1(8):EVIDoa2200015.","DOI":"10.1056\/EVIDoa2200015"},{"issue":"10391","key":"3578_CR18","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853-1865.","journal-title":"Lancet"},{"issue":"5","key":"3578_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.21037\/cco.2016.10.09","volume":"5","author":"L Marcano-Bonilla","year":"2016","unstructured":"Marcano-Bonilla L, Mohamed EA, Mounajjed T, Roberts LR. Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. Chin Clin Oncol. 2016;5(5):61.","journal-title":"Chin Clin Oncol"},{"key":"3578_CR20","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2021011","volume":"43","author":"D Huang","year":"2021","unstructured":"Huang D, Joo H, Song N, Cho S, Kim W, Shin A. Association between gallstones and the risk of biliary tract cancer: a systematic review and meta-analysis. Epidemiol Health. 2021;43:e2021011.","journal-title":"Epidemiol Health"},{"issue":"1","key":"3578_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13027-022-00457-9","volume":"17","author":"Y Wang","year":"2022","unstructured":"Wang Y, Yuan Y, Gu D. Hepatitis B and C virus infections and the risk of biliary tract cancers: a meta-analysis of observational studies. Infect Agent Cancer. 2022:17(1):45.","journal-title":"Infect Agent Cancer"},{"issue":"16","key":"3578_CR22","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.3390\/cells12162098","volume":"12","author":"G Frega","year":"2023","unstructured":"Frega G, Cossio FP, Banales JM, Cardinale V, Macias RIR, Braconi C, et al. Lacking immunotherapy biomarkers for biliary tract cancer: a comprehensive systematic literature review and meta-analysis. Cells. 2023;12(16):2098.","journal-title":"Cells"},{"issue":"1","key":"3578_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.32604\/or.2024.049054","volume":"33","author":"R Kim","year":"2025","unstructured":"Kim R, Park JK, Kwon M, An M, Hong JY, Park JO, et al. Comprehensive molecular characterization to predict immunotherapy response in advanced biliary tract cancer: a phase II trial of pembrolizumab. Oncol Res. 2025;33(1):57\u201365.","journal-title":"Oncol Res"},{"issue":"1","key":"3578_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s12916-025-04263-z","volume":"23","author":"J Ni","year":"2025","unstructured":"Ni J, Li C, Xu X, Xu Q, Yin Q, Chen H, et al. Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers. BMC Med. 2025;23(1):435.","journal-title":"BMC Med"},{"issue":"3","key":"3578_CR25","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.3390\/curroncol30030199","volume":"30","author":"I Garajova","year":"2023","unstructured":"Garajova I, Gelsomino F, Salati M, Leonardi F, De Lorenzo S, Granito A, et al. Bone metastases from intrahepatic cholangiocarcinoma confer worse prognosis. Curr Oncol. 2023;30(3):2613\u201324.","journal-title":"Curr Oncol"},{"key":"3578_CR26","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.1016\/j.annonc.2023.09.1391","volume":"34","author":"S Qin","year":"2023","unstructured":"Qin S, Cai JQ, Li E, Xing B, Zhao L, Dai C, et al. 98P efficacy and safety of durvalumab plus gemcitabine and cisplatin in Chinese participants with advanced biliary tract cancer: extension cohort of the phase III, randomised, double-blind, placebo-controlled, global TOPAZ-1 study. Ann Oncol. 2023;34:S216\u20137.","journal-title":"Ann Oncol"},{"issue":"11","key":"3578_CR27","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1002\/ijc.33751","volume":"149","author":"X Chen","year":"2021","unstructured":"Chen X, Qin S, Gu S, Ren Z, Chen Z, Xiong J, et al. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: a multicenter, phase 2 trial. Int J Cancer. 2021;149(11):1944\u201354.","journal-title":"Int J Cancer"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03578-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03578-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03578-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:01:34Z","timestamp":1787428894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03578-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3578"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03578-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article was revised due to update in Trial Registration section.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zhenggang Ren declares consulting role for MSD, AstraZeneca. Yueyin Pan declares financial interests, personal, and principal investigator with\/for Anhui Provincial Hospital. Wenmiao Wang declares other, personal, full or part-time employment with MSD R&D China Co., Ltd. Nan Li declares financial interests, personal, full or part-time employment with MSD China. Usha Malhotra declares financial interests, personal, full or part-time employment with Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Tingbo Liang, Shanzhi Gu, Hongfeng Gou, Chuang Peng, Tianqiang Song, Haichuan Su, Ke Cao, Houjie Liang, Jieer Ying, Zhimin Geng, Wenchang Yu, Haitao Zhao, Yuxian Bai, Chunyi Hao, Yimin Mao, Wei Li, Lu Wang, Dongliang Li, and Shukui Qin declare they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Helsinki Declaration of 1964, its later amendments, and principles of Good Clinical Practice, and was approved by the appropriate institutional review boards and regulatory agencies. All participants provided written informed consent to participate in the study. Data were collected by the investigators and monitored by an external data monitoring committee.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}